Samer Kasbari, MD
Hematology & Oncology · Goldsboro, NCNPI 1881702595
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,395 of the $162,923 with a category attached, or 80.0%. E.r. Squibb & Sons, L.L.C. accounts for 87.8% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2023 at $52,083 and has fallen 96.2% since, to $1,959 in 2025. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $489.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$143K
- Sanofi$9K
- Lilly USA, LLC$3K
- Novartis$3K
- AstraZeneca$1K
- Bristol Myers Squibb$1K
- plus $3K from 51 others
Across 26 payments — averaging $12,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$212K
- Amgen$111K
- Janssen Research & Development, LLC$11K
- EMD Serono, Inc.$170
What the payments were for
- Consulting fees$5,5603%
- Speaking & faculty fees$130,39580%
- Travel & lodging$18,20011%
- Food & beverage$5,6573%
- Education$7110%
- Other$2,3991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,923 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 99 | $1,677,612 |
| PomalystPomalidomide | 36 | $827,657 |
| XtandiEnzalutamide | 34 | $448,205 |
| DarzalexDaratumumab | 28 | $445,743 |
| TrodelvySacituzumab Govitecan-Hziy | 12 | $354,351 |
| JakafiRuxolitinib Phosphate | 19 | $333,325 |
| KeytrudaPembrolizumab | 23 | $267,357 |
| PromactaEltrombopag Olamine | 11 | $255,159 |
| Lenalidomide | 23 | $247,035 |
| IbrancePalbociclib | 14 | $216,320 |
| TecentriqAtezolizumab | 19 | $206,052 |
| ImbruvicaIbrutinib | 12 | $197,593 |
| ProliaDenosumab | 112 | $188,896 |
| KadcylaAdo-Trastuzumab Emtansine | 17 | $85,790 |
| ZirabevBevacizumab-Bvzr | 18 | $70,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,136 | $1,677,61299 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $142,969 | $827,65736 claims |
| Johnson & JohnsonDarzalex, Xarelto | $201 | $453,32140 claims |
| Astellas Pharma US IncXtandi | $259 | $448,20534 claims |
| PfizerIbrance, Zirabev, Inlyta, Eliquis | $186 | $403,964124 claims |
| GileadTrodelvy | $47 | $354,35112 claims |
| Incyte CorporationJakafi | $148 | $333,32519 claims |
| MerckKeytruda | $110 | $267,35723 claims |
| NovartisPromacta | $2,563 | $255,15911 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $112 | $197,59312 claims |
| AmgenProlia | $28 | $188,896112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Goldsboro
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.